De-merger of Identified Business of Arco Lab Private Limited ( Arco Lab ), a wholly owned subsidiary of the Company

Demerger Ratio AnnouncedNclt Scheme FiledStrategic Transactions View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹663.50

prior close

₹669.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%-1.7% vs market

Pharmaceuticals peers, median of 150sector+0.2%-1.1% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

+0.4

15m

-0.1

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+0.8-1.7+0.2-1.1

Next day

+3.5+2.0+1.6+1.1+2.4

+4.6+0.9+3.7+0.1+4.5

+4.5+1.7+2.8+1.0+3.5

+10.3+1.6+8.8+1.2+9.2

+10.0+2.2+7.8+0.7+9.3

+7.5+2.7+4.7+1.2+6.3

15d

+18.7+4.5+14.1+0.6+18.0

+33.6+5.6+28.0+2.1+31.5

+38.3+9.0+29.3+3.8+34.5

+35.5+3.5+32.0-1.0+36.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Arco Lab Private Limited (a wholly owned subsidiary of Strides Pharma) has approved a Scheme of Arrangement to demerge its Life Sciences and Digital Innovation businesses (called the 'Identified Business') into Pivot Path Private Limited, which is currently a wholly owned subsidiary of Arco Lab. The appointed date for the demerger is April 10, 2025. Shareholders of Arco Lab (i.e., Strides) will receive equity shares of Pivot Path at a 1:1 exchange ratio, with no cash consideration involved. As a result, Arco Lab's investment in Pivot Path will be cancelled, and Pivot Path will become a direct wholly owned subsidiary of Strides. The scheme is subject to shareholder, creditor, and NCLT approvals. Pivot Path will not seek stock exchange listing.

Likely market impact

This is an internal group restructuring with no change in ultimate ownership for Strides shareholders and no cash outflow. It streamlines the corporate structure by placing the Life Sciences and Digital Innovation businesses directly under Strides, potentially enabling sharper focus and future strategic flexibility, though near-term stock impact is expected to be limited.